The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience

The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a mainte...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic advances in respiratory disease Vol. 10; no. 1; pp. 43 - 56
Main Authors Albertson, Timothy E., Richards, John R., Zeki, Amir A.
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.02.2016
SAGE PUBLICATIONS, INC
SAGE Publishing
Subjects
Administration, Inhalation
Androstadienes - administration & dosage
Androstadienes - adverse effects
Androstadienes - therapeutic use
Anti-Asthmatic Agents - administration & dosage
Anti-Asthmatic Agents - adverse effects
Anti-Asthmatic Agents - therapeutic use
Asthma
Asthma - drug therapy
Asthma - physiopathology
Benzyl Alcohols - administration & dosage
Benzyl Alcohols - adverse effects
Benzyl Alcohols - therapeutic use
Chlorobenzenes - administration & dosage
Chlorobenzenes - adverse effects
Chlorobenzenes - therapeutic use
Drug Combinations
Forced Expiratory Volume
Glucocorticoids - administration & dosage
Glucocorticoids - adverse effects
Glucocorticoids - therapeutic use
Humans
Inhalers
Respiratory therapy
Reviews
fluticasone furoate/vilanterol trifenatate
persistent asthma
powder inhaler
long-acting β2 agonist
combined inhaler
inhaled corticosteroid
Online AccessGet full text
ISSN1753-4666
1753-4658
1753-4666
DOI10.1177/1753465815619136

Cover

Abstract The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 μg daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 μg) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.
AbstractList The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 μg daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 μg) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.
The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 μg daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 μg) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.
Author Richards, John R.
Zeki, Amir A.
Albertson, Timothy E.
Author_xml – sequence: 1
  givenname: Timothy E.
  surname: Albertson
  fullname: Albertson, Timothy E.
  email: tealbertson@ucdavis.edu
  organization: Division of Pulmonary, Critical Care Medicine, Department of Internal Medicine and VA Northern California Healthcare Center, Mather UC Davis School of Medicine, 4150 V Street, Suite 3100, Sacramento, CA 95817, USA
– sequence: 2
  givenname: John R.
  surname: Richards
  fullname: Richards, John R.
  organization: Department Emergency Medicine, University of California, Davis, Sacramento, CA, USA
– sequence: 3
  givenname: Amir A.
  surname: Zeki
  fullname: Zeki, Amir A.
  organization: Division of Pulmonary, Critical Care and Sleep Medicine University of California, Davis, Sacramento, CA, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26668137$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAQxy3Uir64c0KROC_EduwkHJBQxaNSpV7aszV2xrteJfbiOCv4AHxvnE0LbSW4-DEz_994PHNGjnzwSMhrWr6jtK7f01rwSoqGCklbyuULcjqbVpWU8ujR-YScjeO2LEVb1s1LcsKyraG8PiW_bjdYmDBo5yG54ItgC9tPyRkYc67CTjFAwgJ8V-xdDz5hDH2RorOYFbPL-SJlyAAe1jigTzMDxrQZ4ENheucz66DIK-5dh94sPPyxw-jm6wU5ttCP-Op-Pyd3Xz7fXn5bXd98vbr8dL0ygjUpl1ILzZnueIvWcloKQTVoqBqojak0lGCwZrVm1lpGKw5MCqttwztohQV-Tq4Wbhdgq3bRDRB_qgBOHQwhrhXEXHuPylJBhSiRC9FUQK2muqJdp6VmmL_VZtbHhbWb9ICdyYVH6J9An3q826h12CvRci4ly4C394AYvk84JrUNU_S5fsV4xSllFZ-j3jxO84f_0MIcIJcAE8M4RrTKuHToZc7qekVLNc-Kej4rWVg-Ez6w_yNZLZIxt_rvc_8Z_xuJX8__
CitedBy_id crossref_primary_10_1016_j_rmed_2018_06_009
crossref_primary_10_21518_2079_701X_2022_16_18_40_48
crossref_primary_10_1080_14656566_2020_1795131
crossref_primary_10_1080_17476348_2016_1227245
Cites_doi 10.1183/09031936.00064513
10.1016/j.rmed.2013.11.009
10.1111/bcp.12019
10.1111/all.12205
10.1186/1471-2466-14-113
10.1002/14651858.CD007949
10.1111/crj.12026
10.1183/09031936.00054213
10.1007/s40262-013-0078-1
10.1056/NEJM199202203260801
10.1016/j.anai.2013.10.013
10.18553/jmcp.2012.18.7.527
10.1183/09031936.00121411
10.1007/s10865-007-9147-y
10.1016/S0140-6736(89)92505-1
10.1016/j.rmed.2014.09.012
10.1016/j.jaci.2010.10.020
10.1016/j.rmed.2014.10.012
10.1136/thx.2009.116608
10.1016/j.clinthera.2014.03.014
10.1016/S0091-6749(95)70206-7
10.4168/aair.2013.5.6.357
10.5414/CP202390
10.1136/adc.67.3.332
10.1007/s00228-015-1894-z
10.1186/1471-2466-13-72
10.1136/bmj.306.6884.1034
10.1016/j.clinthera.2012.06.024
10.1378/chest.129.1.15
10.1016/j.rmed.2014.05.008
10.1016/j.rmed.2012.03.007
10.1016/j.rmed.2012.01.004
10.1586/ecp.13.2
10.1002/cpdd.92
10.1002/phar.1598
10.1186/1465-9921-12-160
10.1016/j.jaci.2006.12.664
10.1016/j.clinthera.2012.11.001
10.1586/17476348.2013.842129
10.1111/jcpt.12316
10.1007/s40265-015-0354-5
10.1016/j.rmed.2013.07.002
10.1378/chest.13-0178
10.5414/CP201822
10.1186/2045-7022-2-11
10.1016/j.jaip.2014.02.010
10.1007/s40262-012-0021-x
10.1001/archinte.1994.00420120066007
10.1111/bcp.12263
10.1136/thoraxjnl-2011-200308
10.1186/1465-9921-12-132
10.1136/thoraxjnl-2012-202606
10.1186/1477-5751-13-9
10.1016/j.pupt.2012.12.001
10.1016/S1081-1206(10)63001-3
10.1186/s12931-014-0088-z
10.1056/NEJM199210223271703
10.3109/02770900903229651
10.1136/thoraxjnl-2013-203600
10.1111/bcp.12243
10.1186/1471-2466-10-1
10.1111/all.12480
ContentType Journal Article
Copyright The Author(s), 2015
The Author(s), 2015.
The Author(s), 2015. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content
The Author(s), 2015 2015 SAGE Publications
Copyright_xml – notice: The Author(s), 2015
– notice: The Author(s), 2015.
– notice: The Author(s), 2015. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content
– notice: The Author(s), 2015 2015 SAGE Publications
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
5PM
DOA
DOI 10.1177/1753465815619136
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
ProQuest Central Premium
ProQuest One Academic
ProQuest - Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
DatabaseTitleList MEDLINE


Publicly Available Content Database
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 7X7
  name: Health & Medical Collection (ProQuest)
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1753-4666
EndPage 56
ExternalDocumentID oai_doaj_org_article_f151550e35584a1fb1b41ddb6b2e753f
PMC5933662
26668137
10_1177_1753465815619136
10.1177_1753465815619136
Genre Journal Article
Review
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: K08 HL114882
GroupedDBID ---
-TM
01A
0R~
123
29Q
4.4
53G
54M
5VS
7X7
8FI
8FJ
AABMB
AABOD
AADUE
AAQDB
AARDL
AARIX
AASGM
ABAFQ
ABAWP
ABEIX
ABFWQ
ABJIS
ABKRH
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACOFE
ACROE
ACRPL
ADBBV
ADEBD
ADNMO
ADOGD
ADYCS
ADZZY
AENEX
AEQLS
AERKM
AEUHG
AEWDL
AEXNY
AFCOW
AFEET
AFKRA
AFKRG
AFRWT
AFUIA
AFWMB
AGNHF
AGQPQ
AHHFK
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
ASPBG
AVWKF
AZFZN
B8M
BCNDV
BDDNI
BENPR
BKSCU
BPHCQ
BSEHC
BVXVI
BYIEH
CAG
CCPQU
CDWPY
CFDXU
COF
CS3
DC-
DC.
DOPDO
EBS
EJD
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HF~
HMCUK
HVGLF
HYE
HZ~
J8X
K.F
N9A
O9-
OK1
P.B
PHGZM
PHGZT
PIMPY
PQQKQ
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
5PM
PUEGO
ID FETCH-LOGICAL-c528t-4675b32bd39eff310551baba48a7cc4ba0ace727b2fff2143a265fbf83da95fa3
IEDL.DBID AFRWT
ISSN 1753-4666
1753-4658
IngestDate Wed Aug 27 01:29:24 EDT 2025
Thu Aug 21 14:09:07 EDT 2025
Mon Jun 30 07:27:43 EDT 2025
Mon Jul 21 05:43:22 EDT 2025
Thu Apr 24 22:50:47 EDT 2025
Tue Jul 01 05:27:05 EDT 2025
Tue Jun 17 22:31:03 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords fluticasone furoate/vilanterol trifenatate
persistent asthma
powder inhaler
long-acting β2 agonist
combined inhaler
inhaled corticosteroid
Language English
License The Author(s), 2015.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c528t-4675b32bd39eff310551baba48a7cc4ba0ace727b2fff2143a265fbf83da95fa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
OpenAccessLink https://www.proquest.com/docview/2343112432?pq-origsite=%requestingapplication%
PMID 26668137
PQID 2343112432
PQPubID 4450849
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_f151550e35584a1fb1b41ddb6b2e753f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5933662
proquest_journals_2343112432
pubmed_primary_26668137
crossref_citationtrail_10_1177_1753465815619136
crossref_primary_10_1177_1753465815619136
sage_journals_10_1177_1753465815619136
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-02-01
PublicationDateYYYYMMDD 2016-02-01
PublicationDate_xml – month: 02
  year: 2016
  text: 2016-02-01
  day: 01
PublicationDecade 2010
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: Thousand Oaks
– name: Sage UK: London, England
PublicationTitle Therapeutic advances in respiratory disease
PublicationTitleAlternate Ther Adv Respir Dis
PublicationYear 2016
Publisher SAGE Publications
SAGE PUBLICATIONS, INC
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: SAGE PUBLICATIONS, INC
– name: SAGE Publishing
References Feehan, Ranker, Durante, Cooper, Jones, Young 2015; 40
Lotvall, Bateman, Busse, O’Byrne, Woodcock, Toler 2014a; 13
Oliver, Vanburen, Allen, Hamilton, Tombs, Inamdar 2014a; 36
Rand, Bilderback, Schiller, Edelman, Hustad, Zeiger 2007; 119
Ingersoll, Cohen 2008; 31
Zeiger, Schatz, Dalal, Qian, Chen, Ngor 2015
Coutts, Gibson, Paton 1992; 67
Brealey, Gupta, Renaux, Mehta, Allen, Henderson 2015; 53
Kempsford, Allen, Bal, Rubin, Tombs 2013a; 75
Lindsay, Heaney 2013b; 7
Busse, Bleecker, Bateman, Lotvall, Forth, Davis 2012; 67
Lin, Kang, Lee, Wang, Zhou, Crawford 2015; 109
McFadden 1995; 96
Woodcock, Bateman, Busse, Lotvall, Snowise, Forth 2011a; 12
Medley, Orozco, Allen 2012; 34
Allen, Schenkenberger, Trivedi, Cole, Hicks, Gul 2013b; 7
Oliver, Vanburen, Allen, Hamilton, Tombs, Kempsford 2014b; 3
Lotvall, Bateman, Bleecker, Busse, Woodcock, Follows 2012; 40
Louie, Zeki, Schivo, Chan, Yoneda, Avdalovic 2013; 6
Bender, Milgrom, Rand 1997; 79
Oliver, Quinn, Goldfrad, Van Hecke, Ayer, Boyce 2012; 2
Bernstein, Bateman, Woodcock, Toler, Forth, Jacques In press
Lindsay, Heaney 2013a; 7
Busse, Bateman, O’Byrne, Lotvall, Woodcock, Medley 2014; 69
Weatherall, Wijesinghe, Perrin, Harwood, Beasley 2010; 65
Woodcock, Bleecker, Busse, Lotvall, Snowise, Frith 2011b; 12
Lee, Yang, Kerwin, Trivedi, Edwards, Pascoe 2015; 109
Crane, Pearce, Flatt, Burgess, Jackson, Kwong 1989; 1
McNally, Rohan, Schluchter, Riekert, Vavrek, Schmidt 2009; 46
Castle, Fuller, Hall, Palmer 1993; 306
Yang, Goyal, Beerahee, Trivedi, Lee, Pascoe 2015; 71
Ni Chroinin, Greenstone, Lasserson, Ducharme 2009; CD005307
Bleecker, Lotvall, O’Byrne, Woodcock, Busse, Kerwin 2014; 2
Nakahara, Wakamatsu, Kempsford, Allen, Yamada, Nohda 2013; 51
Kelloway, Wyatt, Adlis 1994; 154
Price, Robertson, Bullen, Rand, Horne, Staudinger 2010; 10
Cheung, Timmers, Zwinderman, Bel, Dijkman, Sterk 1992; 327
Dransfield, Feldman, Korenblat, Laforce, Locantore, Pistolesi 2014; 108
Spitzer, Suissa, Ernst, Horwitz, Habbick, Cockcroft 1992; 326
O’Byrne, Bleecker, Bateman, Busse, Woodcock, Forth 2014a; 43
Nelson, Weiss, Bleecker, Yancey, Dorinsky, Group 2006; 129
Syed 2015; 75
Kempsford, Oliver, Bal, Tombs, Quinn 2013c; 107
Agusti, De Teresa, De Backer, Zvarich, Locantore, Barnes 2014; 43
Allen, Bareille, Rousell 2013a; 52
Sterling, Lim, Frith, Snowise, Jacques, Haumann 2012; 106
Busse, O’Byrne, Bleecker, Lotvall, Woodcock, Andersen 2013; 68
Chen, Zheng, Jiang, Hu, Wu, Zhuang 2015; 35
O’Byrne, Woodcock, Bleecker, Bateman, Lotvall, Forth 2014b; 15
Shams, Fineman 2014; 112
Woodcock, Lotvall, Busse, Bateman, Stone, Ellsworth 2014; 14
Svedsater, Dale, Garrill, Walker, Woepse 2013; 13
Kempsford, Allen, Kelly, Saggu, Crim 2014; 77
Woodcock, Bleecker, Lotvall, O’Byrne, Bateman, Medley 2013; 144
Bateman, O’Byrne, Busse, Lotvall, Bleecker, Andersen 2014; 69
Kang, Kim, Jung, Song, Cho, Min 2013; 5
Bateman, Bleecker, Lotvall, Woodcock, Forth, Medley 2012; 106
Coleman, Limone, Sobieraj, Lee, Roberts, Kaur 2012; 18
Barnett, Nurmagambetov 2011; 127
Oliver, Bjermer, Quinn, Saggu, Thomas, Yarnall 2013; 68
Allen 2013; 52
Lotvall, Bleecker, Busse, O’Byrne, Woodcock, Kerwin 2014b; 108
Kempsford, Norris, Siederer 2013b; 26
Allen, Bal, Cheesbrough, Hamilton, Kempsford 2014; 77
Allen, Davis, Hardes, Tombs, Kempsford 2012; 34
bibr63-1753465815619136
bibr38-1753465815619136
bibr20-1753465815619136
bibr47-1753465815619136
bibr46-1753465815619136
bibr9-1753465815619136
bibr21-1753465815619136
bibr29-1753465815619136
bibr12-1753465815619136
bibr55-1753465815619136
bibr56-1753465815619136
bibr30-1753465815619136
bibr64-1753465815619136
bibr48-1753465815619136
bibr22-1753465815619136
bibr39-1753465815619136
bibr65-1753465815619136
bibr8-1753465815619136
bibr13-1753465815619136
bibr1-1753465815619136
bibr19-1753465815619136
bibr61-1753465815619136
bibr53-1753465815619136
bibr66-1753465815619136
bibr14-1753465815619136
bibr27-1753465815619136
bibr40-1753465815619136
bibr24-1753465815619136
bibr45-1753465815619136
bibr32-1753465815619136
bibr58-1753465815619136
bibr6-1753465815619136
bibr25-1753465815619136
bibr17-1753465815619136
bibr50-1753465815619136
bibr33-1753465815619136
bibr34-1753465815619136
bibr16-1753465815619136
bibr59-1753465815619136
bibr3-1753465815619136
Zeiger R. (bibr68-1753465815619136) 2015
bibr42-1753465815619136
bibr18-1753465815619136
bibr43-1753465815619136
bibr51-1753465815619136
Lindsay J. (bibr37-1753465815619136) 2013; 7
bibr35-1753465815619136
bibr60-1753465815619136
bibr4-1753465815619136
Bernstein D. (bibr11-1753465815619136)
bibr26-1753465815619136
bibr52-1753465815619136
bibr31-1753465815619136
bibr44-1753465815619136
bibr36-1753465815619136
bibr49-1753465815619136
bibr10-1753465815619136
bibr23-1753465815619136
bibr57-1753465815619136
bibr5-1753465815619136
bibr7-1753465815619136
bibr2-1753465815619136
bibr62-1753465815619136
bibr15-1753465815619136
bibr41-1753465815619136
bibr67-1753465815619136
bibr28-1753465815619136
bibr54-1753465815619136
References_xml – volume: 77
  start-page: 466
  year: 2014
  end-page: 479
  article-title: A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects
  publication-title: Br J Clin Pharmacol
– volume: 69
  start-page: 312
  year: 2014
  end-page: 319
  article-title: Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
  publication-title: Thorax
– volume: 69
  start-page: 1522
  year: 2014
  end-page: 1530
  article-title: Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial
  publication-title: Allergy
– volume: 107
  start-page: 1873
  year: 2013c
  end-page: 1880
  article-title: The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing
  publication-title: Respir Med
– volume: 306
  start-page: 1034
  year: 1993
  end-page: 1037
  article-title: Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment
  publication-title: BMJ
– volume: 127
  start-page: 145
  year: 2011
  end-page: 152
  article-title: Costs of asthma in the United States: 2002–2007
  publication-title: J Allergy Clin Immunol
– volume: 144
  start-page: 1222
  year: 2013
  end-page: 1229
  article-title: Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial
  publication-title: Chest
– volume: 40
  start-page: 590
  year: 2015
  end-page: 593
  article-title: Adherence to controller asthma medications: 6-month prevalence across an US community pharmacy chain
  publication-title: J Clin Pharm Ther
– volume: 96
  start-page: 278
  year: 1995
  end-page: 283
  article-title: Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse
  publication-title: J Allergy Clin Immunol
– volume: 112
  start-page: 9
  year: 2014
  end-page: 12
  article-title: Asthma adherence: how can we help our patients do it better?
  publication-title: Ann Allergy Asthma Immunol
– volume: 108
  start-page: 41
  year: 2014b
  end-page: 49
  article-title: Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomized trial
  publication-title: Respir Med
– volume: 14
  start-page: 113
  year: 2014
  article-title: Efficacy and safety of fluticasone furoate 100 mcg and 200 mcg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomized study
  publication-title: BMC Pulm Med
– volume: 10
  start-page: 1
  year: 2010
  article-title: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study
  publication-title: BMC Pulm Med
– volume: 6
  start-page: 197
  year: 2013
  end-page: 219
  article-title: The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations
  publication-title: Expert Rev Clin Pharmacol
– volume: 34
  start-page: 1683
  year: 2012
  end-page: 1695
  article-title: Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma
  publication-title: Clin Ther
– volume: 13
  start-page: 72
  year: 2013
  article-title: Qualitative assessment of attributes and ease of use of the ellipta dry powder inhaler for delivery of maintenance therapy for asthma and COPD
  publication-title: BMC Pulm Med
– volume: 36
  start-page: 928
  year: 2014a
  end-page: 939
  article-title: Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma
  publication-title: Clin Ther
– volume: 108
  start-page: 1171
  year: 2014
  end-page: 1179
  article-title: Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients
  publication-title: Respir Med
– volume: 109
  start-page: 54
  year: 2015
  end-page: 62
  article-title: The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study
  publication-title: Respir Med
– volume: 327
  start-page: 1198
  year: 1992
  end-page: 1203
  article-title: Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma
  publication-title: N Engl J Med
– year: 2015
  article-title: Utilization and costs of severe uncontrolled asthma in a managed-care setting
  publication-title: J Allergy Clin Immunol Pract
– volume: 7
  start-page: 329
  year: 2013a
  end-page: 336
  article-title: Non-adherence in difficult asthma – facts, myths, and a time to act
  publication-title: Patient Prefer Adherence
– volume: 106
  start-page: 1110
  year: 2012
  end-page: 1115
  article-title: Efficacy and optimal dosing interval of the long-acting beta (2) agonist, vilanterol, in persistent asthma: a randomized trial
  publication-title: Respir Med
– volume: 35
  start-page: 586
  year: 2015
  end-page: 599
  article-title: Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects
  publication-title: Pharmacotherapy
– volume: 109
  start-page: 44
  year: 2015
  end-page: 53
  article-title: Fluticasone furoate/vilanterol 200/25 mcg in asian asthma patients: a randomized trial
  publication-title: Respir Med
– volume: 71
  start-page: 1051
  year: 2015
  end-page: 1058
  article-title: Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma
  publication-title: Eur J Clin Pharmacol
– volume: 43
  start-page: 763
  year: 2014
  end-page: 772
  article-title: A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
  publication-title: Eur Respir J
– volume: 7
  start-page: 397
  year: 2013b
  end-page: 406
  article-title: Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomized, double-blind, placebo-controlled study
  publication-title: Clin Respir J
– volume: 106
  start-page: 642
  year: 2012
  end-page: 650
  article-title: Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial
  publication-title: Respir Med
– volume: 68
  start-page: 513
  year: 2013
  end-page: 520
  article-title: Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomized trial
  publication-title: Thorax
– volume: 119
  start-page: 916
  year: 2007
  end-page: 923
  article-title: Adherence with montelukast or fluticasone in a long-term clinical trial: results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial
  publication-title: J Allergy Clin Immunol
– volume: 65
  start-page: 39
  year: 2010
  end-page: 43
  article-title: Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy
  publication-title: Thorax
– volume: 7
  start-page: 607
  year: 2013b
  end-page: 614
  article-title: Non-adherence in difficult asthma and advances in detection
  publication-title: Expert Rev Respir Med
– volume: 5
  start-page: 357
  year: 2013
  end-page: 364
  article-title: Lost to follow-up in asthmatics does not mean treatment failure: causes and clinical outcomes of non-adherence to outpatient treatment in adult asthma
  publication-title: Allergy Asthma Immunol Res
– volume: 46
  start-page: 921
  year: 2009
  end-page: 927
  article-title: Adherence to combined montelukast and fluticasone treatment in economically disadvantaged African American youth with asthma
  publication-title: J Asthma
– volume: 51
  start-page: 660
  year: 2013
  end-page: 671
  article-title: The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects
  publication-title: Int J Clin Pharmacol Ther
– volume: 18
  start-page: 527
  year: 2012
  end-page: 539
  article-title: Dosing frequency and medication adherence in chronic disease
  publication-title: J Manag Care Pharm
– volume: 75
  start-page: 407
  year: 2015
  end-page: 418
  article-title: Fluticasone furoate/vilanterol: a review of its use in patients with asthma
  publication-title: Drugs
– volume: 67
  start-page: 35
  year: 2012
  end-page: 41
  article-title: Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomized, placebo-controlled trial
  publication-title: Thorax
– volume: 75
  start-page: 1478
  year: 2013a
  end-page: 1487
  article-title: The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects
  publication-title: Br J Clin Pharmacol
– volume: 77
  start-page: 808
  year: 2014
  end-page: 820
  article-title: Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects
  publication-title: Br J Clin Pharmacol
– start-page: 1
  year: In press
  end-page: 11
  article-title: Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma
  publication-title: J Asthma
– volume: 1
  start-page: 917
  year: 1989
  end-page: 922
  article-title: Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study
  publication-title: Lancet
– volume: 53
  start-page: 753
  year: 2015
  end-page: 764
  article-title: Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
  publication-title: Int J Clin Pharmacol Ther
– volume: 67
  start-page: 332
  year: 1992
  end-page: 333
  article-title: Measuring compliance with inhaled medication in asthma
  publication-title: Arch Dis Child
– volume: 12
  start-page: 132
  year: 2011a
  article-title: Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
  publication-title: Respir Res
– volume: 154
  start-page: 1349
  year: 1994
  end-page: 1352
  article-title: Comparison of patients’ compliance with prescribed oral and inhaled asthma medications
  publication-title: Arch Intern Med
– volume: 326
  start-page: 501
  year: 1992
  end-page: 506
  article-title: The use of beta-agonists and the risk of death and near death from asthma
  publication-title: N Engl J Med
– volume: 129
  start-page: 15
  year: 2006
  end-page: 26
  article-title: The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol
  publication-title: Chest
– volume: 79
  start-page: 177
  year: 1997
  end-page: 185
  article-title: Non-adherence in asthmatic patients: is there a solution to the problem?
  publication-title: Ann Allergy Asthma Immunol
– volume: 40
  start-page: 570
  year: 2012
  end-page: 579
  article-title: 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids
  publication-title: Eur Respir J
– volume: CD005307
  year: 2009
  article-title: Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children
  publication-title: Cochrane Database Syst Rev
– volume: 68
  start-page: 1136
  year: 2013
  end-page: 1142
  article-title: Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination
  publication-title: Allergy
– volume: 15
  start-page: 88
  year: 2014b
  article-title: Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial
  publication-title: Respir Res
– volume: 34
  start-page: 2316
  year: 2012
  end-page: 2332
  article-title: Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination
  publication-title: Clin Ther
– volume: 26
  start-page: 256
  year: 2013b
  end-page: 264
  article-title: Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD
  publication-title: Pulm Pharmacol Ther
– volume: 12
  start-page: 160
  year: 2011b
  article-title: Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
  publication-title: Respir Res
– volume: 13
  start-page: 9
  year: 2014a
  article-title: Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids
  publication-title: J Negat Results Biomed
– volume: 3
  start-page: 215
  year: 2014b
  end-page: 221
  article-title: Safety, tolerability, pharmacokinetics, and pharmacodynamics of vilanterol, a novel inhaled long-acting beta-agonist, in children aged 5-11 years with persistent asthma: a randomized trial
  publication-title: Clin Pharmacol Drug Dev
– volume: 52
  start-page: 37
  year: 2013a
  end-page: 42
  article-title: Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate
  publication-title: Clin Pharmacokinet
– volume: 43
  start-page: 773
  year: 2014a
  end-page: 782
  article-title: Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
  publication-title: Eur Respir J
– volume: 52
  start-page: 885
  year: 2013
  end-page: 896
  article-title: The relationship between fluticasone furoate systemic exposure and cortisol suppression
  publication-title: Clin Pharmacokinet
– volume: 2
  start-page: 553
  year: 2014
  end-page: 561
  article-title: Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial
  publication-title: J Allergy Clin Immunol Pract
– volume: 31
  start-page: 213
  year: 2008
  end-page: 224
  article-title: The impact of medication regimen factors on adherence to chronic treatment: a review of literature
  publication-title: J Behav Med
– volume: 2
  start-page: 11
  year: 2012
  article-title: Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomized, controlled trial
  publication-title: Clin Transl Allergy
– ident: bibr49-1753465815619136
  doi: 10.1183/09031936.00064513
– ident: bibr41-1753465815619136
  doi: 10.1016/j.rmed.2013.11.009
– ident: bibr31-1753465815619136
  doi: 10.1111/bcp.12019
– ident: bibr51-1753465815619136
  doi: 10.1111/all.12205
– ident: bibr66-1753465815619136
  doi: 10.1186/1471-2466-14-113
– ident: bibr48-1753465815619136
  doi: 10.1002/14651858.CD007949
– ident: bibr6-1753465815619136
  doi: 10.1111/crj.12026
– ident: bibr1-1753465815619136
  doi: 10.1183/09031936.00054213
– ident: bibr2-1753465815619136
  doi: 10.1007/s40262-013-0078-1
– ident: bibr58-1753465815619136
  doi: 10.1056/NEJM199202203260801
– ident: bibr57-1753465815619136
  doi: 10.1016/j.anai.2013.10.013
– ident: bibr20-1753465815619136
  doi: 10.18553/jmcp.2012.18.7.527
– ident: bibr39-1753465815619136
  doi: 10.1183/09031936.00121411
– ident: bibr28-1753465815619136
  doi: 10.1007/s10865-007-9147-y
– ident: bibr22-1753465815619136
  doi: 10.1016/S0140-6736(89)92505-1
– ident: bibr35-1753465815619136
  doi: 10.1016/j.rmed.2014.09.012
– ident: bibr7-1753465815619136
  doi: 10.1016/j.jaci.2010.10.020
– ident: bibr36-1753465815619136
  doi: 10.1016/j.rmed.2014.10.012
– ident: bibr62-1753465815619136
  doi: 10.1136/thx.2009.116608
– ident: bibr27-1753465815619136
– ident: bibr53-1753465815619136
  doi: 10.1016/j.clinthera.2014.03.014
– ident: bibr43-1753465815619136
  doi: 10.1016/S0091-6749(95)70206-7
– ident: bibr29-1753465815619136
  doi: 10.4168/aair.2013.5.6.357
– ident: bibr13-1753465815619136
  doi: 10.5414/CP202390
– ident: bibr21-1753465815619136
  doi: 10.1136/adc.67.3.332
– ident: bibr67-1753465815619136
  doi: 10.1007/s00228-015-1894-z
– ident: bibr24-1753465815619136
– ident: bibr60-1753465815619136
  doi: 10.1186/1471-2466-13-72
– ident: bibr17-1753465815619136
  doi: 10.1136/bmj.306.6884.1034
– ident: bibr45-1753465815619136
  doi: 10.1016/j.clinthera.2012.06.024
– ident: bibr47-1753465815619136
  doi: 10.1378/chest.129.1.15
– ident: bibr23-1753465815619136
  doi: 10.1016/j.rmed.2014.05.008
– ident: bibr59-1753465815619136
  doi: 10.1016/j.rmed.2012.03.007
– volume: 7
  start-page: 329
  year: 2013
  ident: bibr37-1753465815619136
  publication-title: Patient Prefer Adherence
– ident: bibr8-1753465815619136
  doi: 10.1016/j.rmed.2012.01.004
– ident: bibr42-1753465815619136
  doi: 10.1586/ecp.13.2
– ident: bibr54-1753465815619136
  doi: 10.1002/cpdd.92
– ident: bibr18-1753465815619136
  doi: 10.1002/phar.1598
– ident: bibr64-1753465815619136
  doi: 10.1186/1465-9921-12-160
– ident: bibr56-1753465815619136
  doi: 10.1016/j.jaci.2006.12.664
– ident: bibr5-1753465815619136
  doi: 10.1016/j.clinthera.2012.11.001
– ident: bibr38-1753465815619136
  doi: 10.1586/17476348.2013.842129
– ident: bibr25-1753465815619136
  doi: 10.1111/jcpt.12316
– ident: bibr26-1753465815619136
– ident: bibr61-1753465815619136
  doi: 10.1007/s40265-015-0354-5
– ident: bibr34-1753465815619136
  doi: 10.1016/j.rmed.2013.07.002
– ident: bibr65-1753465815619136
  doi: 10.1378/chest.13-0178
– ident: bibr46-1753465815619136
  doi: 10.5414/CP201822
– start-page: 1
  ident: bibr11-1753465815619136
  publication-title: J Asthma
– ident: bibr52-1753465815619136
  doi: 10.1186/2045-7022-2-11
– ident: bibr12-1753465815619136
  doi: 10.1016/j.jaip.2014.02.010
– ident: bibr4-1753465815619136
  doi: 10.1007/s40262-012-0021-x
– ident: bibr30-1753465815619136
  doi: 10.1001/archinte.1994.00420120066007
– ident: bibr3-1753465815619136
  doi: 10.1111/bcp.12263
– ident: bibr15-1753465815619136
  doi: 10.1136/thoraxjnl-2011-200308
– ident: bibr63-1753465815619136
  doi: 10.1186/1465-9921-12-132
– ident: bibr16-1753465815619136
  doi: 10.1136/thoraxjnl-2012-202606
– ident: bibr40-1753465815619136
  doi: 10.1186/1477-5751-13-9
– ident: bibr33-1753465815619136
  doi: 10.1016/j.pupt.2012.12.001
– year: 2015
  ident: bibr68-1753465815619136
  publication-title: J Allergy Clin Immunol Pract
– ident: bibr10-1753465815619136
  doi: 10.1016/S1081-1206(10)63001-3
– ident: bibr50-1753465815619136
  doi: 10.1186/s12931-014-0088-z
– ident: bibr19-1753465815619136
  doi: 10.1056/NEJM199210223271703
– ident: bibr44-1753465815619136
  doi: 10.3109/02770900903229651
– ident: bibr9-1753465815619136
  doi: 10.1136/thoraxjnl-2013-203600
– ident: bibr32-1753465815619136
  doi: 10.1111/bcp.12243
– ident: bibr55-1753465815619136
  doi: 10.1186/1471-2466-10-1
– ident: bibr14-1753465815619136
  doi: 10.1111/all.12480
SSID ssj0059078
Score 2.0453796
SecondaryResourceType review_article
Snippet The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist...
The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 43
SubjectTerms Administration, Inhalation
Androstadienes - administration & dosage
Androstadienes - adverse effects
Androstadienes - therapeutic use
Anti-Asthmatic Agents - administration & dosage
Anti-Asthmatic Agents - adverse effects
Anti-Asthmatic Agents - therapeutic use
Asthma
Asthma - drug therapy
Asthma - physiopathology
Benzyl Alcohols - administration & dosage
Benzyl Alcohols - adverse effects
Benzyl Alcohols - therapeutic use
Chlorobenzenes - administration & dosage
Chlorobenzenes - adverse effects
Chlorobenzenes - therapeutic use
Drug Combinations
Forced Expiratory Volume
Glucocorticoids - administration & dosage
Glucocorticoids - adverse effects
Glucocorticoids - therapeutic use
Humans
Inhalers
Respiratory therapy
Reviews
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqDqiXqjwbHpUPFVIP0W78zHIDBEJI2xMrcYtsxyNWWrLVEvgH_G_GjjfL0telp0iOn-Ox_U0y_oaQbwy0VkLbXAkHuVBhH_TC5F45hjulB-HCB_3xD3U9ETd38u5NqK_gE9bRA3eCG0A4ceXQBxpwYQqwhRVFXVtlmUeoDWH3xWNsaUx1e7BEky9egsMc2AFZrn5QDkJaSELDBW2VSM28OpAib__vwOavPpNvHL_iWXT1mXxKIJKedZ3fIh98s002x-k3-Q55wcmnqEpo9UbB0zlQmMXP1givPYWnxRwxJjVNTZ-nsyjc-Yy2iyl4LBFeTRuK0JA-9N4xoQ7z2N4_mFO6vE5JY8wP6lNk0lif77mTd8nk6vL24jpP8RZyJ1nZoqC0tJzZmo88AA-hMwtrrBGl0c4Ja4bGecQ7lgEAQ6BlmJJgoeS1GUkwfI9sNDiKL4QaPTQ4Wx7xmxfKWcME1OCcLvHha8jIYCn0yiUy8hATY1YViX_8_TRl5Htf4mdHxPGXvOdhHvt8gUI7JqBiVUmxqn8pVkaOllpQpXX9WDGOgAshEWcZ2e8Uom8FoY4qC64zotdUZa0b62-a6X1k9JYjzpXCOk-CUq2a-9MAD_7HAA_JR0R_yQX9iGy0iyd_jAirtV_jYnoFaaMg8A
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIhLxZstBfmAkDhEu_Ez2wsCRFUhlROV9hbZjoeutE3Kbtp_0P_dGa83y_LoKZIT22N7bH9jT75h7J0Aa42yvjAqQKEMrYNRuSKaIHCljKACHeiffjcnZ-rbTM_ygdsqu1Vu1sS0UDddoDPysZC41eFmJMXHy18FRY2i29UcQuM-e1AiVCGttrPB4NJo-KVf4RCSoxi62l5TjimNktB8QYslETRvt6XE3v8vyPm35-Rv7l9pRzp-zPYzlOSf1mP_hN2L7VP28DRflj9jN6gCHBuHtm_qft4Bh0U6vEaQHTlcLTtEmty1Db-eL1IXdwveL-cQMQe9mrccASK_GHxkqAy36s8v3BHf_FTJU-QPHnN80lReHBiUn7Oz468_vpwUOepCEbSoeuwoq70UvpHTCCApgGbpnXeqcjYE5d3EhYioxwsAEAi3nDAaPFSycVMNTr5gey224hXjzk6ccmVEFBeVCd4JBQ2EYCt8xAZGbLzp9DpkSnKKjLGoy8xC_ucwjdiHIcflmo7jjm8_0zgO3xGRdkrolj_rPC9rIECnJ5FY5lFU8KVXZdN440XE8lDEw40W1Hl2r-qtLo7Yy7VCDLUg4DFVKe2I2R1V2RFj9007P0-83noqpTFY5ntSqm11_2vgwd2yvWaPEN1lF_NDttcvr-IbRFC9f5umyS36vhhR
  priority: 102
  providerName: ProQuest
Title The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience
URI https://journals.sagepub.com/doi/full/10.1177/1753465815619136
https://www.ncbi.nlm.nih.gov/pubmed/26668137
https://www.proquest.com/docview/2343112432
https://pubmed.ncbi.nlm.nih.gov/PMC5933662
https://doaj.org/article/f151550e35584a1fb1b41ddb6b2e753f
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1753-4666
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0059078
  issn: 1753-4666
  databaseCode: RPM
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection (ProQuest)
  customDbUrl:
  eissn: 1753-4666
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0059078
  issn: 1753-4666
  databaseCode: 7X7
  dateStart: 20071001
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1753-4666
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0059078
  issn: 1753-4666
  databaseCode: BENPR
  dateStart: 20071001
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVSPB
  databaseName: Sage Journals GOLD Open Access 2024
  customDbUrl:
  eissn: 1753-4666
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0059078
  issn: 1753-4666
  databaseCode: AFRWT
  dateStart: 20071001
  isFulltext: true
  titleUrlDefault: http://journals.sagepub.com/
  providerName: SAGE Publications
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fa9swEBdtCmMvY_-Xrgt6GIM9eIklWUr2MtrRUAYto7Qsb0aSdWsgcUbqFPYB9r13p8hZs25jTwZbPp2kk_TT3emOsdcCjNHKuEwrD5nStA4GZbOgvcCVMoDypNA_PdMnl-rTpJjssLq9C5N68PoduVUhR3GxptlN2uh-MjL2Kbykwr0TDx943pD6w6qZl2ttd5tUg96QeXo1J8u2J3_I71l7u22X7VHk8qLD9g7H518u2rW7wKNivDyH9JFxfcuweafOrY0sxvv_E0i962t5y2Es7mHjh-xBAp_8cC0tj9hOqB-ze6fJvP6E_UCh4dgVeFqOA8YXwGEW1d0IywOH1XKB2JTbuuI301kclMWMN8spBPyDPk1rjpCSzzdeNUTDXjdXc_uet9cwecwVwkPKaBrphU3M5afscnx88fEkS3kaMl-IYYMdZQonhavkKABISrmZO-usGlrjvXJ2YH1AnOQEAAgEaFboAhwMZWVHBVj5jHVqbMULxq0ZWGXzgLgvKO2dFQoq8N4M8REq6LJ-2-mlT0HMKZfGrMxT3PLfh6nL3m7--LYO4PGPskc0jptyFHo7vlgsv5ZpJpdAELAYBIpLj6yCy53Kq8ppJwLSQxYPWikoW2kuhUSghlBKii57vhaITS0IkfQwl6bLzJaobLGx_aWeXsVI4MVISq2R5hsSql_V_a2B-_9b8CW7j8gwuacfsE6zXIVXiL4a12O7ZmJ6aeLg8-j47PN5L-oyfgLRUS8n
linkProvider SAGE Publications
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIgEXxJuUAnsAJA5W4n06SAjxqlLa9NRKuZnd9Q6NlNpt4oL4AfwdfiOzG9shPHrrydLanp31jGe-2ccMIc8YaK2EtokSDhKhgh30wiReOYaW0oNwYUJ_fKBGR-LTRE42yM_2LEzYVtnaxGioi8qFOfI-4-jq0Blx9ub0LAlVo8LqaltCY6kWe_77NwzZFq93P6B8nzO28_Hw_ShpqgokTrKsRn60tJzZgg89AA8FIlNrrBGZ0c4JawbGefTqlgEAQzhhmJJgIeOFGUowHOleIVcFH4iQq19PugBPYqAZj95hCIDdyGy1LNoPbaEJwyWMkGJC6JUbjNUC_gVx_96p-dt2s-gBd26Rmw10pW-XunabbPjyDrk2bhbn75IfqHIUPybG2lHctAIKszhZjqDeUzifV4hsqSkL-nU6iyKtZrSeT8HjG-HWtKQISOlJtycn0DCL-vjEvKLtIU4aK41Q39RDjfR8l7H5Hjm6FHncJ5sljuIhoUYPjDCpR9TohXLWMAEFOKczvPgCeqTffvTcNSnQQyWOWZ42Wc__FFOPvOzeOF2m_7jg2XdBjt1zIXF3bKjmX_LGDuQQAKQc-JDVHlkFm1qRFoVVlnmkhyxut1qQN9Zkka90v0ceLBWi6wUBlspSrntEr6nKGhvrd8rpccwjLoecK4U0XwSlWnX3vwFuXczbU3J9dDjez_d3D_YekRuILJvt7dtks56f-8eI3mr7JP4ylHy-7H_0F8DpVw8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB5BK1VcKt5dKOADQuIQdmM7dpZbaVmVRyuEWtFbZDuedqVtttqm_AP-N2OvE7oUEKdIsTMej8f2N_F4BuAlR62V1DZT0mEmVVgHvTSZV47TSulRuvBD_-BQ7R_LjyfFSfLNCXdhkgQv3wS3KuIoLtZhdl_UOExnjMMQXVLS1km2B5kbQt2GdbJqNCn1-s7k67ejbikuyPKLd-GoPvGhrp1T3qCxsi_F8P1_wpw3XSev-X_FLWlyFzYTlmQ7y8G_B7d8cx82DtJp-QP4QTrAqGdk_Eb5szkynMW_14SyPcOrxZygJjNNzb5PZ1HG8xlrF1P09EUomjaMECI7751kAg1z2Z6dm7esu1XJYuoP5lOC0kjP9yGUH8Lx5P3R7n6W0i5kruBlS4LShRXc1mLsEUXIoJlbY40sjXZOWjMyzhPssRwROeEtw1WBFktRm3GBRjyCtYZ6sQXM6JGRJvcE47xUzhousUbndEkPX-MAhp3QK5dikofUGLMqT2HIfx-mAbzuv7hYxuP4R913YRz7eiGSdnwxX5xWaWJWGBBdMfIhzDyxija3Mq9rqyz3RI9Y3O60oOqUs-KCcBchI8EH8HipEH0rhHhUmQs9AL2iKitsrJY007MY2LsYC6EU0XwVlOpXc3_r4JP_rfgCNr7sTarPHw4_PYU7hPmS4_k2rLWLK_-McFVrn6fZ8xMIJBo3
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+combination+of+fluticasone+furoate+and+vilanterol+trifenatate+in+the+management+of+asthma%3A+clinical+trial+evidence+and+experience&rft.jtitle=Therapeutic+advances+in+respiratory+disease&rft.au=Albertson%2C+Timothy+E.&rft.au=Richards%2C+John+R.&rft.au=Zeki%2C+Amir+A.&rft.date=2016-02-01&rft.pub=SAGE+Publications&rft.issn=1753-4658&rft.eissn=1753-4666&rft.volume=10&rft.issue=1&rft.spage=43&rft.epage=56&rft_id=info:doi/10.1177%2F1753465815619136&rft_id=info%3Apmid%2F26668137&rft.externalDocID=PMC5933662
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1753-4666&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1753-4666&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1753-4666&client=summon